The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CHRS | +95.03% | -90.45% | -37.48% | -87% |
| S&P | +14.5% | +93.32% | +14.09% | +230% |
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and Coherus COMPLETE. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.
The company fell well short of expectations for its fourth quarter.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $10.25M | -84.2% |
| Gross Profit | $5.84M | -83.5% |
| Gross Margin | 56.98% | 2.5% |
| Market Cap | $84.78M | -57.3% |
| Market Cap / Employee | $0.37M | 0.0% |
| Employees | 228 | -25.5% |
| Net Income | -$44.86M | -247.2% |
| EBITDA | -$44.47M | -130.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $216.89M | 36.2% |
| Accounts Receivable | $5.11M | -97.1% |
| Inventory | 4.5 | -92.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $52.37M | -82.2% |
| Short Term Debt | $1.76M | -57.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -27.59% | -22.5% |
| Return On Invested Capital | -37.81% | -2.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$46.63M | -178.1% |
| Operating Free Cash Flow | -$46.63M | -178.1% |
| Metric | Q4 2024 | YoY Change | |||
|---|---|---|---|---|---|
| Price to Earnings | 7.91 | - | |||
| Price to Book | -1.36 | -1.81 | -0.71 | -0.46 | -80.74% |
| Price to Sales | 0.39 | 0.60 | 0.47 | 0.59 | -7.77% |
| Price to Tangible Book Value | -0.84 | -1.12 | -0.50 | -0.36 | -74.63% |
| Price to Free Cash Flow TTM | 186.99 | - | |||
| Enterprise Value to EBITDA | -66.48 | -9.61 | -7.00 | 2.22 | -112.69% |
| Free Cash Flow Yield | 0.5% | - | |||
| Return on Equity | -860.6% | - | |||
| Total Debt | $299.48M | $298.65M | $299.50M | $54.13M | -81.86% |
CHRS earnings call for the period ending June 30, 2022.
CHRS earnings call for the period ending March 31, 2022.
CHRS earnings call for the period ending December 31, 2021.
CHRS earnings call for the period ending September 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
